Deep-Dive Due Diligence AI Generated Report on cbdMD, Inc. Common Stock (YCBD)
Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.
These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
YCBD_OUT_1 [2025-04-01 15:29:14 -0400] 1889 Bytes | 538 tokens | Cum: 538 tkns (6.73% of 8k)
==========================================================================
Alright, let’s light it up, because it's 3:29:13 PM on Tue Apr 01, 2025 -0400, and I'm charging into cbdMD (YCBD), popping from 0.23 to 0.3233. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!
Here's the first list of news for cbdMD:
C1 - Feb-14-25 02:20AM - cbdMD Inc (YCBD) Q1 2025 Earnings Call Highlights: Achieving Profitability and Debt-Free Status
C2 - Feb-13-25 04:10PM - cbdMD Generates $5.1 Million in Revenue, Positive Earnings
C3 - Feb-07-25 05:26PM - cbdMD, Inc. to Host Conference Call to Discuss December 31, 2024 First Quarter of Fiscal Year 2025 Results
C4 - Jan-15-25 10:30AM - cbdMD Announces It Has Fully Satisfied Its Notes
C5 - Jan-08-25 05:22PM - cbdMD Announces Additional Conversions of Its Convertible Notes
C6 - Jan-03-25 04:44PM - cbdMD, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standard
C7 - Dec-23-24 03:52PM - cbdMD Announces Company's CEO Joins the Board of Directors
C8 - Dec-18-24 04:08PM - cbdMD Generates $19.1 Million in Year Over Year Reduction in Net Loss Improvement
ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on cbdMD (YCBD)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".
YCBD_IN_2 [2025-04-01 15:29:14 -0400] 2 Bytes | 2 tokens | Cum: 540 tkns (6.75% of 8k)
==========================================================================
C1
YCBD_OUT_3 [2025-04-01 15:29:23 -0400] 1098 Bytes | 347 tokens | Cum: 887 tkns (11.09% of 8k)
==========================================================================
Showing C1 (chunk 1 of 5): C1:
**cbdMD Inc (YCBD) Q1 2025 Earnings Call Highlights: Achieving Profitability and Debt-Free Status**
Date: Feb-14-25 02:20AM
Source: (GuruFocus.com)
URL: https://finance.yahoo.com/news/cbdmd-inc-ycbd-q1-2025-072032753.html
Total Net Sales:$5.1 million for Q1 fiscal 2025, a 5% decrease year-over-year and a 12% increase from Q4.
E-commerce Sales:$3.9 million, representing 77% of total net sales, a 10% year-over-year decrease.
Wholesale Sales:$1.1 million, up 22% from the comparative quarter in fiscal 2024.
SDNA Expenses:$3.4 million, down from $4.6 million in the prior year comparative quarter.
Net Income:$15,000 compared to a loss of $977,000 in Q1 fiscal 2024.
Non-GAAP Adjusted EBITDA:$214,000 profit for Q1 fiscal 2025, compared to a $698,000 loss in Q1 fiscal 2024.
Cash and Cash Equivalents:Approximately $2 million as of December 31, 2024.
Working Capital:Approximately $2.8 m
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
YCBD_IN_4 [2025-04-01 15:29:23 -0400] 741 Bytes | 212 tokens | Cum: 1099 tkns (13.74% of 8k)
==========================================================================
CbdMD Inc's Q1 2025 earnings call highlighted the company's achievement of profitability and debt-free status. Total net sales were $5.1 million, a 5% decrease YoY but a 12% increase from Q4. E-commerce sales made up 77% of total net sales at $3.9 million, a decrease of 10% YoY. Meanwhile, wholesale sales increased by 22% YoY to $1.1 million. SDNA expenses decreased to $3.4 million from $4.6 million in Q1 2024. Net income was $15,000, compared to a loss of $977,000 in Q1 2024. The company reported a profit of $214,000 in non-GAAP adjusted EBITDA, compared to a loss of $698,000 in Q1 2024. As of December 31, 2024, the company had approximately $2 million in cash and cash equivalents and approximately $2.8 million in working capital.
YCBD_OUT_5 [2025-04-01 15:29:24 -0400] 1039 Bytes | 323 tokens | Cum: 1422 tkns (17.77% of 8k)
==========================================================================
We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.
A1 - 2025-04-01T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF),...
A2 - 2025-03-31T20:30:07Z - Cannabis Stock Movers For March 31, 2025 - Blueberries Medical (OTC:BBRRF), Belgravia Hartford Cap (...
A3 - 2025-03-28T20:30:07Z - Cannabis Stock Movers For March 28, 2025 - Aurora Cannabis (NASDAQ:ACB), Blueberries Medical (OTC:BB...
A4 - 2025-03-26T20:30:07Z - Marijuana Stock Movers For March 26, 2025 - Cannabix Technologies (OTC:BLOZF), Blueberries Medical (...
A5 - 2025-03-21T20:30:08Z - Cannabis Stock Gainers And Losers From March 21, 2025 - Blueberries Medical (OTC:BBRRF), Belgravia H...
Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.
YCBD_IN_6 [2025-04-01 15:29:24 -0400] 2 Bytes | 2 tokens | Cum: 1424 tkns (17.80% of 8k)
==========================================================================
A1
YCBD_OUT_7 [2025-04-01 15:29:31 -0400] 1098 Bytes | 329 tokens | Cum: 1753 tkns (21.91% of 8k)
==========================================================================
Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF), CARISMA Therapeutics (NASDAQ:CARM)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44591128/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers Reshape Lifesciences RSLS stock moved upwards by 488.1% to $2.12 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. bioAffinity Technologies BIAF stock increased by 236.5% to $0.87. The market value of their outstanding shares is at $13.6 million. As per the news, the Q4 earnings report came out yesterday. Alaunos Therapeutics TCRT shares moved upwards by 55.1% to $2.28. The market value of their outstanding shares is at $3.6 million. Nutex Health NUTX shares moved upwards by 53.55% to $72.
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
YCBD_IN_8 [2025-04-01 15:29:31 -0400] 634 Bytes | 150 tokens | Cum: 1903 tkns (23.79% of 8k)
==========================================================================
This news report highlights the significant movements in health care stocks during Tuesday's intraday trading session. Reshape Lifesciences' stock surged by 488.1% to $2.12, increasing the market value of its outstanding shares to $7.0 million. bioAffinity Technologies also saw a considerable increase, with its stock value rising by 236.5% to $0.87 and the market value of its outstanding shares reaching $13.6 million. This surge followed the release of the Q4 earnings report. Other notable movements include Alaunos Therapeutics, with shares increasing by 55.1% to $2.28, and Nutex Health, which saw shares rise by 53.55% to $72.
YCBD_OUT_9 [2025-04-01 15:29:32 -0400] 1063 Bytes | 317 tokens | Cum: 2220 tkns (27.75% of 8k)
==========================================================================
This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!
B1 - 2024-01-09T18:00:59Z - Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B2 - 2024-01-04T18:37:44Z - Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B3 - 2023-12-29T18:03:42Z - Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B4 - 2023-12-29T13:51:40Z - Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
B5 - 2023-08-31T16:50:39Z - Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B6 - 2023-05-01T13:07:19Z - Why First Republic Bank Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket
Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
YCBD_IN_10 [2025-04-01 15:29:32 -0400] 2 Bytes | 2 tokens | Cum: 2222 tkns (27.77% of 8k)
==========================================================================
B3
YCBD_OUT_11 [2025-04-01 15:29:37 -0400] 1100 Bytes | 321 tokens | Cum: 2543 tkns (31.79% of 8k)
==========================================================================
Showing B3 (chunk 1 of 3): B3:
**Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/23/12/36431408/why-fisker-shares-are-trading-higher-by-over-20-here-are-other-stocks-moving-in-fridays-mid-day-sessShares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business update.
The company grew deliveries by over 300% from Q3 to Q4, and total deliveries are approximately 4,700, with the majority being Fisker Ocean One launch edition vehicles priced at $68,999. In 2023, Fisker produced 10,142 Fisker Oceans and delivered approximately 4,700 vehicles.
Fisker shares jumped 20.8% to $1.8250 on Friday.
Here are some other stocks moving in today's mid-day session.
Gainers
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares climbed 132.6
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
YCBD_IN_12 [2025-04-01 15:29:37 -0400] 415 Bytes | 105 tokens | Cum: 2648 tkns (33.10% of 8k)
==========================================================================
Fisker Inc. shares increased by over 20% during a recent Friday trading session following a business update for December 2023. The company reported a growth in deliveries of over 300% from Q3 to Q4, with total deliveries at around 4,700. The majority of these were Fisker Ocean One launch edition vehicles, priced at $68,999. In 2023, Fisker produced 10,142 Fisker Oceans and delivered approximately 4,700 vehicles.
YCBD_OUT_13 [2025-04-01 15:29:38 -0400] 1064 Bytes | 309 tokens | Cum: 2957 tkns (36.96% of 8k)
==========================================================================
This is our list of SEC filings.
If empty, the search returned no recent filings.
S1 - 2025-02-13 10-Q PART 1 FIN INFO
ITEM 1. FIN STATEMENTS.
cbdMD, INC.
COND CONS BAL SHEETS
December 31, 2024 & SEPTEMBER 30, 2024
(Unaudited)
(Unaudited)
December 31,
September 30,
2024
2024
Assets
Curr assets:
Cash and cas...
S2 - 2024-12-18 10-K ITEM 7.
MGT'S DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.
The following discussion of our financial condition and results of operations should be read in conjunction with the audited CONS financial statements and the notes to thos...
S3 - 2024-11-27 8-K Item 1.01. Entry into a Material Definitive Agrmt.
Effective November 26, 2024, cbdMD, Inc. (the Company) entered into a Second Amendment to Lease (the Amendment) to extend the Warehouse Lease entered into on August 27, 2019 (the Lease) for approximately 80,000 square feet ...
Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
YCBD_IN_14 [2025-04-01 15:29:38 -0400] 2 Bytes | 2 tokens | Cum: 2959 tkns (36.99% of 8k)
==========================================================================
S1
YCBD_OUT_15 [2025-04-01 15:29:47 -0400] 1098 Bytes | 373 tokens | Cum: 3332 tkns (41.65% of 8k)
==========================================================================
Showing S1 (chunk 1 of 6): S1:
PART 1 FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
cbdMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
December 31, 2024 AND SEPTEMBER 30, 2024
(Unaudited)
(Unaudited)
December 31,
September 30,
2024
2024
Assets
Current assets:
Cash and cash equivalents
$ 1,970,217 $ 2,452,553 Accounts receivable
1,272,846 983,910 Inventory
2,116,136 2,365,187 Inventory prepaid
356,819 159,006 Prepaid sponsorship
7,126 21,754 Prepaid expenses and other current assets
637,559 406,674 Total current assets
6,360,703 6,389,084 Other assets:
Property and equipment, net
511,915 454,268 Operating lease assets
1,209,338 85,817 Deposits for facilities
62,708 62,708 Intangible assets
2,698,313 2,889,580 Investment in other securities, noncurrent
700,000 700,000 Total other assets
5,182,274 4,192,373 Total assets
$ 11,542,977 $ 10,581,457
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
YCBD_IN_16 [2025-04-01 15:29:47 -0400] 548 Bytes | 125 tokens | Cum: 3457 tkns (43.21% of 8k)
==========================================================================
The financial statements for cbdMD, INC. for December 31, 2024 and September 30, 2024 were presented. Their total assets increased from $10,581,457 in September to $11,542,977 in December. The current assets remained relatively stable at around $6.3 million for both periods. However, there was a noticeable increase in other assets from $4,192,373 in September to $5,182,274 in December, largely due to an increase in operating lease assets and a small increase in property and equipment. Intangible assets decreased slightly over the same period.
YCBD_OUT_17 [2025-04-01 15:29:58 -0400] 4169 Bytes | 1194 tokens | Cum: 4651 tkns (58.14% of 8k)
==========================================================================
This is our set of metrics.
Please analyze the numbers.
+--------------------+-----------------------+-----------------------+------------------------+
| Volume: 13,291,530 | Perf Month: -15.09% | Option/Short: No / No | Sales Y/Y TTM: -18.02% |
+--------------------+-----------------------+-----------------------+------------------------+
| Avg Volume: 1.94M | Perf Quarter: -15.99% | Short Float: 8.02% | ROE: -60.98% |
+--------------------+-----------------------+-----------------------+------------------------+
| Rel Volume: 7.72 | Index: - | Short Ratio: 0.22 | ROI: -282.01% |
+--------------------+-----------------------+-----------------------+------------------------+
| RSI (14): 49.39 | Market Cap: 1.98M | Short Interest: 0.43M | Sales Surprise: - |
+--------------------+-----------------------+-----------------------+------------------------+
| ATR (14): 0.05 | Shs Outstand: 5.54M | Beta: 2.59 | EPS Surprise: - |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA20: 10.59% | Shs Float: 5.40M | Sales Q/Q: -4.87% | P/E: - |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA50: -24.27% | Inst Own: 2.96% | Sales past 5Y: 2.35% | Earnings: Feb 13 AMC |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA200: -34.87% | Insider Own: 13.73% | Employees: 42 | |
+--------------------+-----------------------+-----------------------+------------------------+
| Perf Week: 19.06% | Insider Trans: 0.00% | Debt/Eq: 0.92 | |
+--------------------+-----------------------+-----------------------+------------------------+
The next section covers any insider trading.
If this section may be blank due to no recent filings.
[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A
[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 5113476.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 15095, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A
[Price Metrics - Last 30 Days]
Latest Close: 0.326
Average Volume: 904120.32
30-Day High: 0.373
30-Day Low: 0.23
[Detailed Financials: Q1 2025]
- Total Assets: $11,542,977.0
- Total Liabilities: $9,761,386.0
- Total Equity: $1,781,591.0
- Current Assets: $6,360,703.0
- Current Liabilities: $9,169,803.0
[Income Statement: Q1 2025]
- Revenue: $5,113,476.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.22
[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-164,387
[Detailed Financials: FY 2024]
- Total Assets: $10,581,457.0
- Total Liabilities: $8,618,040.0
- Total Equity: $1,963,417.0
- Current Assets: $6,389,084.0
- Current Liabilities: $8,618,040.0
[Income Statement: FY 2024]
- Revenue: $19,482,167.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.79
[Cash Flow Statement: FY 2024]
- Net Cash Flow: $654,693
==== END OF FINANCIAL REPORT ====
You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.
Now, complete this report with the following:
1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE
YCBD_IN_18 [2025-04-01 15:29:58 -0400] 1083 Bytes | 253 tokens | Cum: 4904 tkns (61.30% of 8k)
==========================================================================
1) Brief Summary: The company has experienced a significant decline in its performance over the past month (-15.09%) and quarter (-15.99%). Its sales have dropped year on year, with a reduction of 18.02%. On top of this, the company's return on equity (ROE) and return on investment (ROI) figures are quite poor, standing at -60.98% and -282.01% respectively. However, the company's weekly performance shows a positive sign with a 19.06% increase. This suggests some potential for short-term recovery if the company can maintain this momentum.
2) MARKET_SCORE[40]: Given the company's recent poor financial performance and negative ROI and ROE figures, there is a 40% likelihood of an upward move in the short term, based on the recent positive weekly performance.
3) PRICE_TARGET[$0.43]: Considering the company's recent signs of short-term recovery, I project a potential 34% increase from the latest close price of $0.326, which would put the target price at approximately $0.43.
4) AI_RPT_HEADLINE: "Despite Negative ROI and ROE, Company Shows Signs of Short-Term Recovery."
YCBD_OUT_19 [2025-04-01 15:30:03 -0400] 676 Bytes | 167 tokens | Cum: 5071 tkns (63.39% of 8k)
==========================================================================
Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)
YCBD_IN_20 [2025-04-01 15:30:03 -0400] 511 Bytes | 100 tokens | Cum: 5171 tkns (64.64% of 8k)
==========================================================================
This would largely depend on the specifics of the analysis I was conducting. However, generally speaking, I would likely choose X2 - More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes. This is because these documents contain a wealth of valuable information that can help to more accurately assess a company's financial health and potential future performance. Furthermore, they can shed light on factors that may not be immediately apparent from simply looking at a company's
YCBD_IN_21 [2025-04-01 15:30:03 -0400] 126 Bytes | 29 tokens | Cum: 5200 tkns (65.00% of 8k)
==========================================================================
====================================
[2025-04-01 15:30:03] # Analysis Completed
Elapsed Time: 50.34 seconds